Accessibility Menu
Nyxoah logo

Nyxoah(NASDAQ) NYXH

Market Cap$140.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-94%
5 Year-96%
1 Year-81%
1 Month-21%
$1.38
-2.13%
-0.03Today
After hours$1.38+$0.00 (+0.00%)
Nyxoah last closing stock price
MetricPriceDate
Last closeUSD 1.402026-07-31
Nyxoah stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.402026-07-24
1 month-21.35%USD 1.782026-07-01
3 month-53.33%USD 3.002026-05-01
Year to date-69.57%USD 4.602025-12-31
1 year-81.23%USD 7.462025-07-31
3 year-83.05%USD 8.262023-08-01
5 year-95.68%USD 32.432021-07-30
Since inception-94.17%USD 24.002021-04-28

Nyxoah Financials at a Glance

Market Cap

$140.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€16.32M

Net Income (TTM)

-€86.12M

EPS (TTM)

-$2.47

P/E Ratio

-0.57

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$1.38

Volume

332,694

Open

$1.40

Previous Close

$1.40

Daily Range

$1.35 - $1.41

52-Week Range

$1.26 - $8.59

Estimated Earnings Date

Aug 5, 2026

NYXH News

featured-earnings-leadership-highlights.png

Nyxoah Q2 Revenue Jumps 74 Percent

Motley Fool Markets TeamAug 18, 2025

NYXH: Motley Fool Moneyball Superscore

50

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nyxoah

Nyxoah S.A. is a medical technology company focused on developing and commercializing innovative solutions for obstructive sleep apnea (OSA). The company's flagship product, the Genio system, offers a minimally invasive hypoglossal neurostimulation therapy designed for patients with moderate to severe OSA.

Products and Services
  • Genio system: A CE-Marked neurostimulation therapy for OSA
  • Patient-centric approach to treatment and care
  • Focus on minimally invasive medical technologies
Growth Outlook
  • Significant market potential in the OSA treatment sector
  • Continued investment in research and development to enhance product offerings
  • Expansion plans targeting new geographical markets
Financial Highlights
  • Recent quarterly revenue of €7.36 million, showing growth potential
  • Trailing twelve months (TTM) revenue of €19.64 million, indicating upward trend
  • Cash and short-term investments totaling €26.03 million as of Q1 2026
Nyxoah S.A. operates in the healthcare sector, specifically within the medical specialties industry. The company was founded in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. With a dedicated team of 163 employees, Nyxoah is committed to addressing the challenges of obstructive sleep apnea through innovative solutions. The Genio system represents a significant advancement in the treatment of OSA, providing a patient-friendly alternative to traditional therapies. The growth outlook for Nyxoah is promising, driven by the increasing prevalence of sleep apnea and the demand for effective treatment options. The company's focus on research and development aims to enhance its product portfolio and expand its market reach. Financially, Nyxoah has demonstrated a solid revenue trajectory, with recent quarterly results reflecting a positive trend. The company's cash reserves position it well for future investments and operational needs, further supporting its growth strategy. Overall, Nyxoah S.A. presents an intriguing opportunity for investors interested in the healthcare technology sector, particularly in innovative solutions for sleep disorders.
AI Generated • Jul 26, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

153.7

CEO

Olivier Taelman, EMBA

Website

www.nyxoah.com

Headquarters

Mont-Saint-Guibert, WA 1435, BE

NYXH Financials

Key Financial Metrics (TTM)

Gross Margin

48.34%

Operating Margin

-527.24%

Net Income Margin

-527.77%

Return on Equity

-164.44%

Return on Capital

-90.97%

Return on Assets

-87.91%

Earnings Yield

-1.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$140.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

100.07M

Volume

332.69K

Avg. Volume

309.96K

Financials (TTM)

Gross Profit

€7.89M

Operating Income

-€86.04M

EBITDA

-€77.16M

Operating Cash Flow

-€71.96M

Capital Expenditure

-€1.32M

Free Cash Flow

-€73.28M

Cash & ST Invst.

€26.03M

Total Debt

€36.22M

Nyxoah Performance Analysis

Nyxoah annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,241,205221.9%
20232023-12-31EUR 4,700,69145.0%
20242024-12-31EUR 4,890,3244.0%
20252025-12-31EUR 11,308,351131.2%
Nyxoah sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.9%
Q32025-09-3047.2%
Q42025-12-31186.2%
Q12026-03-3130.4%
Nyxoah annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.27-7.4%
20232023-12-31EUR -1.6731.4%
20242024-12-31EUR -1.9617.2%
20252025-12-31EUR -2.6736.3%
Nyxoah sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.3%
Q32025-09-30-14.5%
Q42025-12-316.3%
Q12026-03-3137.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€7.36M

+591.9%

Gross Profit

€2.22M

+237.5%

Gross Margin

30.16%

N/A

Market Cap

$140.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$859.52K

N/A

Employees

163

N/A

Net Income

-€18.42M

+17.7%

EBITDA

-€14.63M

+31.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€26.03M

-58.7%

Total Debt

€36.22M

+64.0%

Accounts Receivable

€9.25M

+61.3%

Inventory

€4.36M

-12.4%

Long Term Debt

€18.96M

-9.0%

Short Term Debt

€17.26M

+1276.2%

Return on Assets

-87.91%

N/A

Return on Invested Capital

-1.52%

N/A

Free Cash Flow

-€22.36M

-19.4%

Operating Cash Flow

-€21.63M

-16.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STIMNeuronetics, Inc.
$1.98+0.51%
IVVDInvivyd, Inc.
$0.54-8.01%
KRMDKORU Medical Systems, Inc.
$4.11+0.00%
TARAProtara Therapeutics, Inc.
$3.92-2.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About NYXH

What is the current price of Nyxoah?

Nyxoah is trading at $1.40 per share.

What is the 52-week range for Nyxoah?

Over the past 52 weeks, Nyxoah has traded between $1.26 and $8.59.

How much debt does Nyxoah have?

As of the most recent reporting period, Nyxoah reported total debt of €41.57M.

How much cash does Nyxoah have on hand?

Nyxoah reported €14.90M in cash and cash equivalents in its most recent financial results.

What is Nyxoah’s dividend yield?

Nyxoah does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services